Hengrui Medicine launches first share buyback, repurchasing 335,000 A-shares for 14.5 million yuan
On September 17, 2026, Chinese pharmaceutical company Hengrui Medicine (600276) initiated its first-ever share buyback, repurchasing 335,000 A-shares for 14.5 million yuan via centralized bidding. The buyback, approved on August 19, 2026, plans to use 1-2 billion yuan of company funds over one year. Repurchased shares will support an employee stock ownership plan for up to 1,269 participants. The company reported first-half 2026 revenue of 15.456 billion yuan and net profit of 4.465 billion yuan.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary covers the current reports
Cross-source coverage
Reporting timeline
Hengrui Medicine launches first share buyback worth 14.5 million yuan
Hengrui Medicine (600276), a Chinese pharmaceutical giant with a market cap of 285.6 billion yuan, has initiated its first-ever share buyback. On September 17, the company repurchased 335,000 A-shares through centralized bidding, spending 14.5 million yuan at prices between 43.10 and 43.58 yuan per share. This follows board approval on August 19 for a larger repurchase plan of 1 to 2 billion yuan, with a maximum price of 81.78 yuan per share, to be executed over one year. The repurchased shares will fund an employee stock ownership plan, with up to 12.855 million shares to be offered to 1,269 participants at 26.21 yuan each. The company reported first-half 2026 revenue of 15.456 billion yuan, with innovative drug sales rising 16.38% year-on-year to 8.809 billion yuan, and net profit of 4.465 billion yuan, up 0.34%.
Read sourceHengrui Medicine Launches First Share Buyback Worth Up to 2 Billion Yuan
Hengrui Medicine (600276), a leading Chinese pharmaceutical company with a market cap of 286.9 billion yuan, has initiated its first-ever share buyback. On September 17, the company repurchased 335,000 A-shares for 14.5 million yuan, at prices between 43.10 and 43.58 yuan per share. This follows a board-approved plan from August 19 to repurchase between 1 billion and 2 billion yuan worth of shares, at a maximum price of 81.78 yuan per share, over a one-year period ending August 18, 2027. The buyback is funded from the company's own resources and aims to support an employee stock ownership plan. The draft plan allows up to 1,269 participants, including directors and senior management, to acquire shares at a transfer price of 26.21 yuan each. In the first half of 2026, Hengrui reported operating revenue of 15.456 billion yuan, with innovative drug sales rising 16.38% year-on-year to 8.809 billion yuan, and net profit of 4.465 billion yuan.
Read sourceHengrui Medicine Buys Back 335,000 A-Shares in First Tranche of Plan
On September 17, 2026, Hengrui Medicine conducted its first share repurchase of A-share stocks via centralized bidding, buying back 335,000 shares, representing 0.005% of its total share capital. The highest transaction price was RMB 43.58 per share and the lowest was RMB 43.10 per share, with a total payment of RMB 14.5036 million. According to the previously disclosed plan, the company intends to use its own funds to repurchase shares for an employee stock ownership plan, with a total repurchase amount ranging from no less than RMB 1 billion to no more than RMB 2 billion. The repurchase period runs from August 19, 2026, to August 18, 2027.
Show 2 older updatesHide older updates
Hengrui Medicine Repurchases 335,000 A-Shares for First Time, Paying 14.5 Million Yuan
According to a report by Cailian Press on September 17, Hengrui Medicine (600276.SH) announced in a filing that it repurchased 335,000 A-share stocks through centralized bidding transactions for the first time today. The repurchased shares account for 0.005% of its total share capital. The highest transaction price was RMB 43.58 per share and the lowest was RMB 43.10 per share, with a total payment of RMB 14.5036 million. Under a previously approved plan, the company intends to use its own funds to repurchase shares via centralized bidding for an employee stock ownership plan, with a total repurchase amount ranging from no less than RMB 1 billion to no more than RMB 2 billion. The repurchase period runs from August 19, 2026, to August 18, 2027.
Read sourceHengrui Medicine Launches First Share Buyback Worth Up to 2 Billion Yuan
Hengrui Medicine (600276), a leading Chinese pharmaceutical company with a market cap of 286.9 billion yuan, initiated its first share buyback on September 17, 2026, repurchasing 335,000 A-shares for 14.5 million yuan. The buyback, approved by the board on August 19, 2026, plans to use 1-2 billion yuan of the company's own funds to repurchase up to 24.46 million shares at a maximum price of 81.78 yuan per share, over a one-year period. The repurchased shares will be used for an A-share employee stock ownership plan, which aims to acquire up to 12.86 million shares at 26.21 yuan per share for up to 1,269 participants, including directors and senior management. The company's 2026 semi-annual report showed operating revenue of 15.456 billion yuan, with innovative drug sales up 16.38% year-on-year to 8.809 billion yuan, and net profit of 4.465 billion yuan, up 0.34%.
Read source